Gilberto Ruiz Deya, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.0%), education and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Merck at 31.3% of the total. Reporting peaked in 2021 at $7,998 and has fallen 70.1% since, to $2,390 in 2025.
Across 167 payments — averaging $189.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$10K
- Olympus Latin America, Inc.$7K
- Intuitive Surgical$6K
- Olympus Corporation Of The Americas$5K
- Johnson & Johnson$1K
- Medtronic$466
- plus $2K from 20 others
Across 74 payments — averaging $16,081 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
What the payments were for
- Consulting fees$4,82515%
- Speaking & faculty fees$11,06035%
- Travel & lodging$2,2467%
- Food & beverage$4,29414%
- Education$9,15529%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 23 | $9,870 |
| Olympus Latin America, Inc. | 12 | $7,235 |
| Intuitive Surgical | 8 | $5,612 |
| Olympus Corporation Of The Americas | 8 | $4,827 |
| Johnson & Johnson(2 entities) | 43 | $1,308 |
| Medtronic | 7 | $466 |
| Boston Scientific | 5 | $337 |
| Pfizer | 3 | $281 |
| Ferring Pharmaceuticals Inc. | 7 | $244 |
| AbbVie(2 entities) | 6 | $212 |
| PBG Puerto Rico LLC | 10 | $208 |
| Bard Peripheral Vascular, Inc. | 2 | $136 |
| E.r. Squibb & Sons, L.L.C. | 2 | $128 |
| Tolmar, Inc. | 6 | $108 |
| Neotract Inc. | 2 | $94 |
| Progenics Pharmaceuticals, Inc. | 1 | $92 |
| Teleflex LLC | 3 | $90 |
| Verity Pharmaceuticals Inc. | 4 | $81 |
| AstraZeneca | 1 | $55 |
| Novo Nordisk | 2 | $42 |
| Bayer Puerto Rico Inc. | 2 | $37 |
| Travere Therapeutics, Inc. | 3 | $35 |
| Pharmaand GmbH | 2 | $33 |
| BD | 1 | $25 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$7,825
- EVIS EXERA$4,572
- DAVINCI XI$4,500
- VISERA ELITE II VIDEO SYSTEM CENTER$4,305
- ThunderBeat$2,460
- Da Vinci Surgical System$1,039
- Olympus Surgical Accessories$654
- Dextile$139
- SpaceOAR VUE System - 10mL$134
- Signia$124
- ADSTILADRIN$113
- OPDIVO$101
How this compares
$31,580 in reported general payments places this provider in the 85th percentile of 122 urology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 128 | $1,815,345 |
| ErleadaApalutamide | 30 | $572,574 |
| MyrbetriqMirabegron | 288 | $154,124 |
| ZytigaAbiraterone Acetate | 11 | $119,208 |
| Tolterodine Tartrate ErTolterodine Tartrate | 1,126 | $87,266 |
| ElmironPentosan Polysulfate Sodium | 50 | $58,705 |
| Tamsulosin Hcl | 2,439 | $23,841 |
| Estradiol | 189 | $16,434 |
| Potassium Citrate ErPotassium Citrate | 157 | $10,410 |
| Finasteride | 697 | $7,190 |
| Sildenafil Citrate | 294 | $4,336 |
| Ciprofloxacin Hcl | 583 | $4,261 |
| Ketoconazole | 152 | $3,492 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 143 | $2,850 |
| Diclofenac Sodium | 364 | $2,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Zytiga | $1,308 | $691,78241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 122 urology providers in Puerto Rico.
Other urology in Ponce
- Claudio Bernaschina BobadillaPonce$132K
- Mariela Martinez-RiveraPonce$105K
- Javier CastilloPonce$41K
- Giovanni Gonzalez AlboPonce$13K
- Richard Baez TelladoPonce$10K
- Rafael BritoPonce$4K
- Jan VazquezPonce$3K
- Felix Mendoza RosaPonce$3K
- Adrian Santana ParacchiniPonce$2K
- Freddy Mendez TorresCayey$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.